viewPharmaxis Ltd

Pharmaxis has the "secret sauce" for developing drugs through to commercialisation

Pharmaxis Ltd (ASX:PXS) non-executive director Dr Kathleen Metters explains what attracted her to the board of the pharmaceutical research company less than a year ago, following a long and illustrious career in big pharma.

"This is an incredibly innovative research group. They have managed to move into the clinic - and not just into the clinic but into pre-clinical development - compounds for particular, what we call, therapeutic targets to test new mechanisms that has never been done in the industry before," says Metters.

"I realised they just had all the qualities to do it again and again and again. They are really rigorous scientists... they know every step of the business; this is a small company but it goes from research through to commercialisation, so they have really exquisite line of sight on what they need to do to bring forward new therapies," Metters continues.

Pharmaxis is in talks for a partnership deal on its LOXL2 anti‐fibrotic program, with hopes of announcing a partner in the second half of this year.

Quick facts: Pharmaxis Ltd

Price: 0.076 AUD

Market: ASX
Market Cap: $30.04 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...



Pharmaxis Ltd expects review of Bronchitol NDA to be completed by mid-2020

Pharmaxis Ltd (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) CEO Gary Phillips speaks to Proactive's Andrew Scott after it was announced its US licensee Chiesi Farmaceutici SpA filed a resubmission to the FDA for Bronchitol® . The move addresses issues raised by the US Food and Drug Administration (FDA)...

on 6/5/20

2 min read